
Keywords: mTOR inhibitor; Temsirolimus; Interstitial lung disease; Drug-induced pneumonia; Acute exacerbation; AaDO2; alveolar-arterial oxygen gradient; CMV; cytomegalovirus; CRP; C-reactive protein; DAD; diffuse alveolar damage; DILD; Drug-induced interstitial lun